JP Nadda says Govt vigilant about quality of medicines

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-07-27T16:26:53+05:30 | Updated On 6 Aug 2024 12:33 AM IST

New Delhi: The Indian government reassured that it has a robust system in place for examining medicines and has taken necessary actions regarding recent concerns about the quality of certain cough syrups exported to Africa. Minister of Chemicals and Fertilizers J.P. Nadda provided these assurances while addressing the Lok Sabha.

Nadda's remarks followed a query from Congress member Gaurav Gogoi, who had raised concerns over some cough syrups exported to Africa. The Minister emphasized that the government is closely monitoring the quality of medicines and is committed to preventing any future issues.

There is a robust system of examination of medicines in place, the minister said during the Question Hour and emphasised that the world's most effective and cheapest medicines are produced in India

Speaker Om Birla said there is a demand for medicines from India in all the countries he had been to as he has asked the government to increase exports of the medicines globally.

To a query on whether the government has taken note of certain comments of the Department of Pharmaceuticals against the reputation of small drugmakers, Nadda said a complaint was received against an Assistant Section Officer for sending an email to pharma associations using language that is not officially proper.

"Even though the communication was informal, a show-cause notice was issued to the concerned officer. The officer has apologised for the same. Nevertheless, competent authority has rejected the reply and initiated departmental proceedings against the erring officer," the minister said.

The Revamped Pharmaceuticals Technology Upgradation Scheme (PTUAS) is aimed at helping the pharmaceutical industry align its production process with best global standards, he said adding more than 100 applications have been received since the application window was opened from April 11, 2024.

"Seven applications have been approved and all the seven are MSMEs," he said.

Read also: JP Nadda addresses rising cancer cases, medicine affordability

JP naddacogh syrupDepartment of Pharma

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751